Cargando…

An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms

Chemoresistance limits its clinical implementation for pancreatic ductal adenocarcinoma (PDAC). We previously generated an EGFR/HER2 targeted conjugate, dual-targeting ligand-based lidamycin (DTLL), which shows a highly potent antitumor effect. To overcome chemoresistance in PDAC, we aim to study DT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Hongjuan, Song, Wenping, Cao, Rui, Ye, Cheng, Zhang, Li, Chen, Hebing, Wang, Junting, Shi, Yuchen, Li, Rui, Li, Yi, Liu, Xiujun, Zhou, Xiaofei, Shao, Rongguang, Li, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489697/ https://www.ncbi.nlm.nih.gov/pubmed/36127339 http://dx.doi.org/10.1038/s41467-022-33037-x

Ejemplares similares

Internal enhancement of DNA damage by a novel bispecific antibody‐drug conjugate‐like therapeutics via blockage of mTOR and PD‐L1 signal pathways in pancreatic cancer
por: Cao, Rui, et al.
Publicado: (2019)

Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine
por: Li, Hua, et al.
Publicado: (2017)

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway
por: Zhou, Yunjiang, et al.
Publicado: (2019)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine
por: Huai, Yanyan, et al.
Publicado: (2019)

Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
por: Blaauboer, Amber, et al.
Publicado: (2020)

Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition
por: IOANNOU, NIKOLAOS, et al.
Publicado: (2016)

STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer
por: Liu, Chao, et al.
Publicado: (2019)

CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine
por: Xu, Peng, et al.
Publicado: (2016)

A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Targeting CD44 and Gli1 of Gastric Cancer Stem Cells
por: Yao, Hongjuan, et al.
Publicado: (2020)

Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
por: Wu, Yifen, et al.
Publicado: (2015)

Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine
por: Yin, Tao, et al.
Publicado: (2016)

Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
por: Chen, Ru, et al.
Publicado: (2017)

Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway
por: Zhang, Tianli, et al.
Publicado: (2022)

Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma
por: ZHAO, XIN, et al.
Publicado: (2013)

Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment
por: Wu, Lin-Wen, et al.
Publicado: (2019)

A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway
por: Wu, Xiaohan, et al.
Publicado: (2023)

Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2
por: Bae, Kieun, et al.
Publicado: (2022)

YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine
por: Zhou, Ling, et al.
Publicado: (2019)

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
por: Assenat, Eric, et al.
Publicado: (2015)

Thymoquinone affects the gemcitabine sensitivity of pancreatic cancer by regulating collagen via hypoxia inducible factor-1α
por: Zhao, Zhanxue, et al.
Publicado: (2023)

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma
por: Richard, Corentin, et al.
Publicado: (2018)

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
por: Azorsa, David O, et al.
Publicado: (2009)

Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II
por: Awasthi, Niranjan, et al.
Publicado: (2013)

DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine
por: Liu, Fang, et al.
Publicado: (2014)

Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine
por: DUONG, HONG-QUAN, et al.
Publicado: (2013)

Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels
por: Panebianco, Concetta, et al.
Publicado: (2021)

Pancreatic cancer cells spectral library by DIA-MS and the phenotype analysis of gemcitabine sensitivity
por: Kong, Ran, et al.
Publicado: (2022)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
por: Pignochino, Ymera, et al.
Publicado: (2010)

Gemcitabine-induced heparanase promotes aggressiveness of pancreatic cancer cells via activating EGFR signaling
por: Song, Jin-Wen, et al.
Publicado: (2017)

Inactivation of XPF Sensitizes Cancer Cells to Gemcitabine
por: George, Joseph W., et al.
Publicado: (2019)

Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine
por: Isayev, Orkhan, et al.
Publicado: (2014)

Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
por: Tang, Yong, et al.
Publicado: (2012)

Correction: DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine
Publicado: (2014)

Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine
por: Duong, Hong-Quan, et al.
Publicado: (2013)

bcl-2-specific siRNAs restore Gemcitabine sensitivity in human pancreatic cancer cells
por: Okamoto, Kinya, et al.
Publicado: (2007)

YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine
por: Jiang, Zhengdong, et al.
Publicado: (2016)

TLE2 is associated with favorable prognosis and regulates cell growth and gemcitabine sensitivity in pancreatic cancer
por: Hu, Shixiong, et al.
Publicado: (2020)

Permeability evaluation of gemcitabine-CPP6 conjugates in Caco-2 cells
por: Ferreira, Abigail, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h0upr9lbtt6ejvnaah91ldher9